Bayesian network meta-analysis to evaluate interferon-free treatments in naive patients with genotype 1 hepatitis C virus infection.

Fig. 1. (a) Estimates of SVR12 achievement, medians with 95% CrIs, calculated by the Bayesian model. The numerical values of these estimates are as follows: SOF/LED-12 weeks, 93.17 (95% CrI: 98.35–99.76); SOF/LED-8 weeks, 77.84 (95% CrI: 93.64–98.71); SOF/DAC, 87.62 (95% CrI: 99.56–100); ARIOD, 83.42 (95% CrI: 93.88–97.93); and ARIODR, 93.15 (95% CrI: 97.27–99.12). (b) Histograms of rankings estimated by the probabilistic analysis. Overall, the rankings in effectiveness for the five treatments were as follows: (i) SOF/DAC-12 weeks; (ii) SOF/LED-12 weeks; (iii) ARIODR-12 weeks; and (iv) ARIOD-12 weeks and SOF/LED-8 weeks (with the same median rank). CrIs, credible intervals; ARIOD-12 weeks, ABT-450/ritonavir/ombitasvir/dasabuvir for 12 weeks; ARIODR-12 weeks, ARIOD+ ribavirin for 12 weeks; SOF/DAC-12 weeks, sofosbuvir+daclatasvir for 12 weeks; SOF/LED-8 weeks, sofosbuvir+ ledipasvir for 8 weeks; SOF/LED-12 weeks, sofosbuvir+ ledipasvir for 12 weeks.